This study demonstrated that early amlexanox administration in acute sepsis mice could lessen inflammatory response and S100A12 expression, lowering AF risk and suggesting its efficacy in preventing and treating new-onset AF in sepsis. Here, S100A12 is linked to atrial fibrillation.